公开(公告)号：US20050169923A1

公开(公告)日：2005-08-04

申请号：US11053536

申请日：2005-02-07

Applicant: Mark de Boer ,  Leah Conroy

Inventor： Mark de Boer ,  Leah Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  C12N5/06

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US06127299A

公开(公告)日：2000-10-03

申请号：US734986

申请日：1996-10-22

Applicant: Mark de Boer ,  Johannes Wilhelmus Maria Sonnemans ,  Pankaj Himatlal Desai ,  Jaap Enters

Inventor： Mark de Boer ,  Johannes Wilhelmus Maria Sonnemans ,  Pankaj Himatlal Desai ,  Jaap Enters

IPC: B01J23/652 ,  B01J23/85 ,  B01J23/88 ,  B01J23/94 ,  B01J27/186 ,  B01J35/10 ,  B01J37/00 ,  B01J38/00 ,  B01J38/02 ,  B01J38/04 ,  B01J38/12 ,  C10G45/08 ,  C10G49/02 ,  C10G49/04 ,  B01J23/92

CPC classification number: C10G49/04 ,  B01J23/85 ,  B01J35/023 ,  B01J35/026 ,  B01J35/1038 ,  B01J35/1047 ,  B01J35/1061 ,  B01J35/1085 ,  B01J35/109 ,  B01J37/0009 ,  B01J37/0036 ,  B01J38/00 ,  B01J38/04 ,  B01J38/12 ,  C10G49/02

Abstract: The present invention relates to a process for preparing a catalyst suitable for the hydroprocessing of heavy hydrocarbon feeds, which process comprises the steps of(i) if necessary removing carbonaceous and sulphurous deposits from waste catalyst by subjecting the waste catalyst to a thermal treatment,(ii) grinding the waste catalyst obtained in step (i),(iii) mixing the ground material obtained in step (ii) with a binder and, optionally, additives, and(iv) shaping the mixture to form a new catalyst,wherein the loss on ignition of the catalyst composition mixture at any point in the steps (ii), (iii), and (iv) is not higher than 70%.The process according to the invention is suitable, int. al., for the production of ebullated bed catalysts. In that case, it is envisaged to incorporate a macroporous additive into the catalyst composition. Spent hydroprocessing catalyst which has been used for hydroprocessing light hydrocarbon feedstocks is particularly suitable for use in the process according to the invention.

Abstract translation: 本发明涉及一种制备适用于重烃进料加氢处理的催化剂的方法，该方法包括以下步骤：（i）如果需要，通过对废催化剂进行热处理从废催化剂中除去碳质和硫化物沉积物（ ii）研磨步骤（i）中获得的废催化剂，（iii）将步骤（ii）中获得的研磨材料与粘合剂和任选的添加剂混合，和（iv）使混合物成形以形成新的催化剂，其中 在步骤（ii），（iii）和（iv）中的任何一点，催化剂组合物混合物的灼烧失重不高于70％。 根据本发明的方法是合适的， 用于生产沸腾床催化剂。 在这种情况下，设想在催化剂组合物中加入大孔添加剂。 已经用于加氢处理轻烃原料的废加氢处理催化剂特别适用于本发明的方法。

公开(公告)号：US07361345B2

公开(公告)日：2008-04-22

申请号：US11053536

申请日：2005-02-07

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: A61K39/395 ,  C07K16/28 ,  C12N5/12

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US06899879B2

公开(公告)日：2005-05-31

申请号：US09954764

申请日：2001-09-18

Applicant: Mark de Boer ,  Leah B Conroy

Inventor： Mark de Boer ,  Leah B Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者中IgE介导的过敏性疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US20070098720A1

公开(公告)日：2007-05-03

申请号：US11613409

申请日：2006-12-20

Applicant: David Thomas ,  Mark de Boer ,  Pieter Res ,  Peter Simons

Inventor： David Thomas ,  Mark de Boer ,  Pieter Res ,  Peter Simons

IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/28

CPC classification number: A61K39/39541 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2300/00

Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Abstract translation: 公开了可以结合并刺激专业和非专业人抗原呈递细胞（“APC”）的激动剂抗CD40分子，包括单克隆抗体，增强CD40L对CD40阳性细胞的刺激作用和/或诱导表型成熟 的单核细胞来源的树突状细胞。 提供了几种这样的单克隆抗体，并且生产它们的细胞系已经保藏在美国典型培养物保藏中心。

公开(公告)号：US6004552A

公开(公告)日：1999-12-21

申请号：US469015

申请日：1995-06-05

Applicant: Mark de Boer ,  Leah B Conroy

Inventor： Mark de Boer ,  Leah B Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531

CPC classification number: C07K16/2878 ,  A61K39/395 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者中抗体介导的死亡酶的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US5747034A

公开(公告)日：1998-05-05

申请号：US200716

申请日：1994-02-18

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: C12N15/02 ,  A61K31/436 ,  A61K31/445 ,  A61K31/56 ,  A61K31/57 ,  A61K31/70 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  C07H21/04 ,  C07K14/705 ,  C07K16/28 ,  C07K16/42 ,  C12N5/00 ,  C12N5/10 ,  C12P21/08 ,  C12R1/91 ,  C07K16/18 ,  C12N5/12

CPC classification number: C07K16/2827 ,  A61K39/395 ,  C07K14/70532 ,  C07K16/2878 ,  A61K2039/505 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/30 ,  C12N2799/026 ,  Y10S530/809

Abstract: Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce antigen-specific tolerance. The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

Abstract translation: 抗B7-1抗体或其他B7-1配体可用于预防或治疗患者中T细胞介导的免疫系统疾病或诱导抗原特异性耐受。 抗B7-1抗体可用于引起T细胞无反应性，治疗同种异体移植排斥反应，治疗移植物抗宿主病，以及预防或治疗类风湿性关节炎。 免疫抑制剂与抗体共同施用。

公开(公告)号：US20090311268A1

公开(公告)日：2009-12-17

申请号：US12420481

申请日：2009-04-08

Applicant: David Thomas ,  Mark de Boer ,  Pieter C.J.M. Res ,  Peter J. Simons

Inventor： David Thomas ,  Mark de Boer ,  Pieter C.J.M. Res ,  Peter J. Simons

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07H21/04 ,  C12N5/10

CPC classification number: A61K39/39541 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2300/00

Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Abstract translation: 公开了可以结合并刺激专业和非专业人抗原呈递细胞（“APC”）的激动剂抗CD40分子，包括单克隆抗体，增强CD40L对CD40阳性细胞的刺激作用和/或诱导表型成熟 的单核细胞来源的树突状细胞。 提供了几种这样的单克隆抗体，并且生产它们的细胞系已经保藏在美国典型培养物保藏中心。

公开(公告)号：US20090130095A1

公开(公告)日：2009-05-21

申请号：US12049850

申请日：2008-03-17

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US07172759B2

公开(公告)日：2007-02-06

申请号：US09773866

申请日：2001-02-01

Applicant: David Thomas ,  Mark de Boer ,  Pieter C. J. M. Res ,  Peter J. Simons

Inventor： David Thomas ,  Mark de Boer ,  Pieter C. J. M. Res ,  Peter J. Simons

IPC: A61K39/395 ,  C07K16/28

CPC classification number: A61K39/39541 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2300/00

Abstract: Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40.

Abstract translation: 公开了使用不阻断CD40L与CD40的结合的激动剂抗CD40抗体诱导抗原呈递细胞成熟的细胞毒性T淋巴细胞应答的方法。